Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This abstract reviews 5α-reductase inhibitors and their side effects in patients with sexual dysfunction but reports no new findings.

Validated method reliably measures finasteride in tablets using liquid chromatography.

This study found that torilin from Torilis japonica fruit extract inhibited 5 alpha-reductase in vitro more effectively than alpha-linolenic acid but less effectively than finasteride.

This study found that domestic and imported finasteride tablets were bioequivalent in terms of their pharmacokinetic parameters and relative bioavailability in human volunteers.

This erratum addresses the long-term effects of finasteride on prostate-specific antigen levels but reports no new research findings.

This study reports that dutasteride, used alone or with tamsulosin, effectively reduces acute urine retention and surgery risk in men with benign prostatic hyperplasia, and may lower prostate cancer incidence, suggesting potential chemopreventive benefits.

Finasteride slightly improves prostate symptoms but has minimal difference from placebo.

Dutasteride reduces DHT more effectively than finasteride.

This study concluded that finasteride granules are bioequivalent to finasteride tablets based on pharmacokinetic evaluation in healthy male volunteers.

In this study, researchers developed a coamorphous form of tadalafil and finasteride, showing improved solubility and dissolution in vitro, with results successfully translated in vivo in rats. They reported reasonable stability, suggesting this form could serve as a therapeutic alternative to the current marketed combination.

This study found that tamsulosin and finasteride may improve cardiac function and reduce prostatic volume in elderly male patients with chronic heart failure and benign prostatic hyperplasia.

In this study, researchers used a UV-Vis Spectrophotometer to qualitatively and quantitatively analyze Dutasteride residues in human plasma, achieving a total recovery rate of 64.992%, and determined that the BTB reagent effectively selected compounds not analyzed in their research.

This study found that two finasteride preparations were bioequivalent in human volunteers when tested using a new HPLC method for pharmacokinetics.

This study reports that finasteride chewable tablets may be effective in treating benign prostatic hyperplasia due to their stable formulation and ease of production.

In this randomized trial of Iranian men with moderate to severe androgenetic alopecia, researchers found that both finasteride and dutasteride improved hair density over 24 weeks, with dutasteride showing stronger PSA reduction but similar safety to finasteride.

Finasteride and dutasteride may cause macular abnormalities.

This review discusses current treatments for benign prostatic hyperplasia and reports on the cost-effectiveness of alpha1-selective adrenergic receptor antagonists compared to other pharmacologic and invasive therapies without presenting new clinical results.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

This study found that finasteride and its combination with terazosin significantly reduced PSA levels in patients with benign prostatic hyperplasia, whereas terazosin alone showed no clinically significant effect.

This review discusses the use of platelet-rich plasma injections for treating erectile dysfunction, noting the potential for regenerative medicine to reverse or halt disease progression, but it reports no new clinical results.

This review summarizes the adverse effects associated with 5α‐reductase inhibitors, noting slightly increased rates of decreased libido, erectile and ejaculatory dysfunction, gynecomastia, depression, and anxiety, with further studies needed to explore symptom prevalence and persistence.

This study developed and validated ultraviolet spectrophotometric and reversed phase high performance liquid chromatographic methods for simultaneously estimating Tamsulosin and Finasteride in tablet form, showing statistical validation and effectiveness in pharmaceutical analysis.

This study found that dutasteride use is associated with increased reports of sexual dysfunction, based on data from the U.S. Food and Drug Administration Adverse Event Reporting System.

This research highlights the shift from surgical to pharmacologic and less invasive treatments for benign prostatic hyperplasia, noting finasteride's effectiveness in men with enlarged prostates and its ability to reduce acute urinary retention risk compared to alpha-blockers.

This study found that topically applied minoxidil was more effective than nitroglycerin and placebo in enhancing penile diameter, rigidity, and arterial flow, with the most pronounced effects in patients with neurogenic impotence.

This review discusses the use of finasteride and alpha antagonists for symptomatic benign prostatic hypertrophy and suggests current studies are evaluating combination therapies as potential non-surgical alternatives.

This study reviews the significant prevalence of organic etiologies, especially vascular causes, in erectile dysfunction among men under 40 and emphasizes thorough evaluation and consideration of treatment options like exercise and PDE-5 inhibitors.

In this study, a new Finasteride conjugate showed stronger inhibition of 5α-reductase and similar reduction of prostate hyperplasia in rats compared to Finasteride, with potentially improved toxicity.